CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric Label
Question
CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric Label
Direct answer
FDA pediatric label approval broadens addressable patient volumes, driving Casgevy revenue run-rates higher for CRSP and Vertex. — bullish pressure on CRSP via commercial product revenue inflection.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-09
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric Label”, revision 1, evidence through 2026-09-09. https://marketontology.com/catalysts/2026-09-09/crispr-therapeutics-casgevy-revenue-surges-78-qoq-to-76m-on-pediatric-label-5f23cb
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| CRSP | ▲Bull | 1–4 weeks | commercial product revenue inflection | 61 |
| VRTX | ▲Bull | 1–4 weeks | commercial partnership royalty expansion | 54 |
| XBI | ▲Bull | 1–5 days | clinical-stage biotech sentiment spillover | 42 |
CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric Label
FDA pediatric label approval broadens addressable patient volumes, driving Casgevy revenue run-rates higher for CRSP and Vertex. — bullish pressure on CRSP via commercial product revenue inflection.
Casgevy revenue expanded 78% quarter-over-quarter to $76 million with pediatric approval.
- SourceCasgevy revenue expanded 78% quarter-over-quarter to $76 million with pediatric approval.
- TransmissionFDA pediatric label approval broadens addressable patient volumes, driving Casgevy revenue run-rates higher for CRSP and Vertex.
- SummaryCRISPR Therapeutics posted 78% sequential revenue growth for Casgevy to $76 million. The FDA approved a pediatric label expansion down to age 2. Shares rallied 19% over the prior month on accelerating commercial adoption.
- CRSPDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- CRSP closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- CRSP price vs. pre-event level
- CRSP volume vs. 20-day average
CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric Label
FDA pediatric label approval broadens addressable patient volumes, driving Casgevy revenue run-rates higher for CRSP and Vertex. — bullish pressure on VRTX via commercial partnership royalty expansion.
Vertex co-develops and commercializes Casgevy globally with CRISPR Therapeutics.
- SourceVertex co-develops and commercializes Casgevy globally with CRISPR Therapeutics.
- TransmissionFDA pediatric label approval broadens addressable patient volumes, driving Casgevy revenue run-rates higher for CRSP and Vertex.
- SummaryCRISPR Therapeutics posted 78% sequential revenue growth for Casgevy to $76 million. The FDA approved a pediatric label expansion down to age 2. Shares rallied 19% over the prior month on accelerating commercial adoption.
- VRTXDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- VRTX closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- VRTX price vs. pre-event level
- VRTX volume vs. 20-day average
CRISPR Therapeutics Casgevy Revenue Surges 78% QoQ to $76M on Pediatric Label
FDA pediatric label approval broadens addressable patient volumes, driving Casgevy revenue run-rates higher for CRSP and Vertex. — bullish pressure on XBI via clinical-stage biotech sentiment spillover.
CRSP commercial progress provides proof-of-concept valuation support for broader gene-editing baskets.
- SourceCRSP commercial progress provides proof-of-concept valuation support for broader gene-editing baskets.
- TransmissionFDA pediatric label approval broadens addressable patient volumes, driving Casgevy revenue run-rates higher for CRSP and Vertex.
- SummaryCRISPR Therapeutics posted 78% sequential revenue growth for Casgevy to $76 million. The FDA approved a pediatric label expansion down to age 2. Shares rallied 19% over the prior month on accelerating commercial adoption.
- XBIDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- XBI closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- XBI price vs. pre-event level
- XBI volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| XBI | Bullishdisagreed | 159.38 2026-09-09 | -1.61% | -3.26% | Pending |
| VRTX | Bullishdisagreed | 521.12 2026-09-09 | -1.26% | -1.51% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Why CRISPR Therapeutics Stock Rocked the Market Last Month · financial_press · 2026-09-08
Related catalysts
- 2026-10-19Viking Therapeutics raises $575M via equity and convertible notesVKTX XBI
- 2026-10-19Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO CongressXBI ZNTL
- 2026-10-19Zentalis Reports 15.8-Month Median OS for Azenosertib at ESMO CongressXBI
- 2026-10-19Viking Therapeutics raises $575M via equity and convertible notesXBI
- 2026-10-06Spyre Therapeutics Prices $350 Million Public Equity Offering at $85 Per ShareSYRE XBI
- 2026-10-04Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug TrialGMAB XBI
- 2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on NasdaqADRX XBI-3.04%
- 2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on NasdaqADRX XBI-3.04%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.